Mineralys Therapeutics News

Latest Mineralys Therapeutics Stock News & MLYS Headlines

87,400 Shares of Mineralys Therapeutics, Inc. $MLYS Acquired by ACT Capital Partners L.P.

13 hours ago | defenseworld.net

Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

7 days ago | globenewswire.com

Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)

10 days ago | seekingalpha.com

What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call

11 days ago | marketbeat.com

Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript

11 days ago | seekingalpha.com

Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

11 days ago | globenewswire.com

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

12 days ago | globenewswire.com

Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

18 days ago | globenewswire.com

Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International

19 days ago | globenewswire.com

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

24 days ago | globenewswire.com

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

Market Closed

MLYS

Mineralys Therapeutics

$ 15.33

-1.10%

Last 24H

Trading with leverage comes with a high risk and may not be suitable for everyone.

Portfolio

Updated 2 days ago

Top

Gainers

Losers

Symbol

Last Price

24H CNG

Mineralys Therapeutics News

Latest Mineralys Therapeutics Stock News & MLYS Headlines

Download App

People Also Watch

Explore our Tools